Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 159

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.46 Daily Weekly Monthly
20 Day Moving Average: 684,891 shares
Shares Outstanding: 73.81 (millions)
Market Capitalization: $1,657.75 (millions)
Beta: 0.38
52 Week High: $25.15
52 Week Low: $16.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.34% -9.02%
12 Week -4.59% -11.80%
Year To Date 12.36% 2.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 innoviva@argotpartners.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo - Chairman
Stephen Basso - Chief Financial Officer
Jules Haimovitz - Director
Sarah Schlesinger - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 73.81
Most Recent Split Date: (:1)
Beta: 0.38
Market Capitalization: $1,657.75 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.96 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 11.46
Trailing 12 Months: 5.31
PEG Ratio: -
Price Ratios
Price/Book: 1.24
Price/Cash Flow: 4.46
Price / Sales: 3.94
EPS Growth
vs. Year Ago Period: 76.00%
vs. Previous Quarter: -77.32%
Sales Growth
vs. Year Ago Period: 10.56%
vs. Previous Quarter: -14.50%
ROE
03/31/26 - 33.33
12/31/25 - 37.63
09/30/25 - 28.17
ROA
03/31/26 - 22.67
12/31/25 - 23.60
09/30/25 - 16.23
Current Ratio
03/31/26 - 21.13
12/31/25 - 14.64
09/30/25 - 14.12
Quick Ratio
03/31/26 - 20.07
12/31/25 - 13.85
09/30/25 - 13.33
Operating Margin
03/31/26 - 83.97
12/31/25 - 81.07
09/30/25 - 55.53
Net Margin
03/31/26 - 119.89
12/31/25 - 65.92
09/30/25 - 32.78
Pre-Tax Margin
03/31/26 - 142.63
12/31/25 - 79.46
09/30/25 - 40.29
Book Value
03/31/26 - 18.18
12/31/25 - 15.71
09/30/25 - 13.51
Inventory Turnover
03/31/26 - 2.67
12/31/25 - 2.47
09/30/25 - 2.09
Debt-to-Equity
03/31/26 - 0.19
12/31/25 - 0.22
09/30/25 - 0.25
Debt-to-Capital
03/31/26 - 16.13
12/31/25 - 18.02
09/30/25 - 20.31
 

Powered by Zacks Investment Research ©